9781588292001 - combination cancer therapy: modulators and potentiators (cancer drug discovery and development) (8 Ergebnisse)
Sprache: Englisch
Verlag: Humana, 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USARomtrade Corp.
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 80,24
Versand nach gratisVersand innerhalb von USAAnzahl: 2 verfügbar
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Sprache: Englisch
Verlag: Humana Press, 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: Majestic Books, Hounslow, Vereinigtes KönigreichMajestic Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Neu
EUR 73,31
EUR 7,63 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 4 verfügbar
Zustand: New. pp. 296 Illus.
Sprache: Englisch
Verlag: Humana, 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: Studibuch, Stuttgart, DeutschlandStudibuch
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht - Sehr gut
EUR 11,99
EUR 80,70 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
hardcover. Zustand: Sehr gut. 294 Seiten; 9781588292001.2 Gewicht in Gramm: 500.
Sprache: Englisch
Verlag: Humana, 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USARomtrade Corp.
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 100,39
Versand nach gratisVersand innerhalb von USAAnzahl: 1 verfügbar
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Sprache: Englisch
Verlag: Humana, 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 166,57
EUR 14,05 VersandVersand von Vereinigtes Königreich nach USAAnzahl: Mehr als 20 verfügbar
Zustand: New. In.
Sprache: Englisch
Verlag: Humana Press, 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: moluna, Greven, Deutschlandmoluna
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 178,14
EUR 48,99 VersandVersand von Deutschland nach USAAnzahl: Mehr als 20 verfügbar
Gebunden. Zustand: New. Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interactio.
Sprache: Englisch
Verlag: Humana Press Inc., 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: Kennys Bookstore, Olney, MD, USAKennys Bookstore
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 255,30
EUR 9,18 VersandVersand innerhalb von USAAnzahl: 15 verfügbar
Zustand: New. Reviews those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and details their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. Editor(s): Schwartz, Gary E., Ph.D. Series: Cancer Drug Discover…y and Development. Num Pages: 284 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 235 x 155 x 17. Weight in Grams: 1310. . 2004. Hardback. . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: Humana Press Dez 2004, 2004
Serie: Cancer Drug Discovery and Development, Buch 34 von 96. Buch 34 von 96 - Cancer Drug Discovery and Development
- Hardcover
Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 247,94
EUR 63,13 VersandVersand von Deutschland nach USAAnzahl: 2 verfügbar
Buch. Zustand: Neu. Neuware - Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The com…binations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy. Early clinical trials of the new molecular-based anticancer agents have shown that many are marginal in controlling cancer, but prove to be potent modulators and potentiators of chemotherapy-induced apoptosis when used in combination with classic cytotoxic drugs or radiation. In Combination Cancer Therapy: Modulators and Potentiators, expert physician-scientists and clinicians with first-hand experience in the clinical development of targeted therapies review those combinations that hold the most promise for the future of medical oncology, detailing their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory benchtop to the patient's bedside as a new generation of cancer therapeutics. Cutting-edge and forward-looking, Combination Cancer Therapy: Modulators and Potentiators offers everyone in the fields of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects for cancer patients today.
